Introduction: Despite life-saving antiretroviral drugs, an effective HIV-1 vaccine is the best solution and likely a necessary component of any strategy for halting the AIDS epidemic. The currently prevailing aim is to pursue antibody-mediated vaccine protection. With ample evidence for the ability of T cells to control HIV-1 replication, their protective potential should be also harnessed by vaccination. The challenge is to elicit not just any, but protective T cells.Areas covered: This article reviews the clinical experience with the first-generation conserved-region immunogen HIVconsv delivered by combinations of plasmid DNA, simian adenovirus, and poxvirus MVA. The aim of our strategy is to induce strong and broad T cells targeting functionally important parts of HIV-1 proteins common to global variants. These vaccines were tested in eight phase 1/2 preventive and therapeutic clinical trials in Europe and Africa, and induced high frequencies of broadly specific CD8+ T cells capable of in vitro inhibition of four major HIV-1 clades A, B, C and D, and in combination with latency-reactivating agent provided a signal of drug-free virological control in early treated patients.Expert opinion: A number of critical T-cell traits have to come together at the same time to achieve control over HIV-1.

中文翻译：

---

旨在保护性T细胞反应：在预防和治疗性临床试验中，重点关注第一代保守区HIVconsv疫苗。

简介：尽管有挽救生命的抗逆转录病毒药物，有效的HIV-1疫苗是遏制AIDS流行的任何策略的最佳解决方案，并且可能是必要的组成部分。当前的主要目标是追求抗体介导的疫苗保护。有足够的证据表明T细胞具有控制HIV-1复制的能力，因此疫苗接种也应发挥其保护潜力。面临的挑战不仅是要引发保护性T细胞，而且还要引起保护性T细胞。涉及的领域：本文回顾了质粒DNA，猿猴腺病毒和痘病毒MVA联合提供的第一代保守区免疫原HIVconsv的临床经验。我们策略的目的是诱导针对广泛变异体常见的HIV-1蛋白质功能重要部分的强大而广泛的T细胞。